Angiotensin receptor blockers: baseline therapy in hypertension? by Messerli, Franz H. et al.
ESC HOT LINE COMMENTARY
Angiotensin receptor blockers: baseline
therapy in hypertension?
Franz H. Messerli1*, Sripal Bangalore2, and Frank Ruschitzka3
1St. Luke’s Roosevelt Hospital and Columbia University, New York, NY 10019, USA; 2Brigham and Women’s Hospital, Boston, MA, USA; and 3University Hospital,
Zurich, Switzerland
Online publish-ahead-of-print 31 August 2009
This commentary refers to ‘Effects of valsartan on mor-
bidity and mortality in uncontrolled hypertensive patients
with high cardiovascular risks: KYOTO HEART Study’†,
by T. Sawada et al., on page 2461
The provocative editorial by Verma and Strauss in the BMJ 5 years
ago1 stating that angiotensin receptor blockers (ARBs) ‘may
increase myocardial infarction—and patients may need to be
told’ caused a tempest in the teapot and led to extensive scrutiny
of outcome data with this drug class. In 2007 the blood pressure-
lowering treatment trialists collaboration found that there were
similar blood pressure-dependent effects of angiotensin-converting
enzyme (ACE) inhibitors and ARBs for the risk of stroke, coronary
heart disease, and heart failure.2 The authors cautioned, however,
that only for ACE inhibitors but not for ARBs, was there evidence
of a blood pressure-independent effect on the risk of major coron-
ary disease events. Also, ONTARGET, a thorough, double-blind
prospective randomized trial, documented equal outcome efficacy
of an ARB and an ACE inhibitor in a high-risk population, although
there was a trend for better stroke prevention in the ARB (telmi-
sartan) arm and better coronary artery disease prevention in the
ACE inhibitor (ramipril) arm.3 When analysing these studies and
including the most recent ARB trials such as TRANSCEND,4
PRoFESS,5 CASE-J trial,6 HIJ-CREATE,7 JIKEI,8 and KYOTO,9 we
found, in a database of 100 000 patients from 26 randomized
non-heart failure trials of ARBs, a 13% reduction in the risk of
stroke (P ¼ 0.022) (Figure 1) but a trend towards increased risk
of myocardial infarction, especially when compared with active
treatment (P ¼ 0.06) (Figure 2).
Much ink has been wasted on the outcome of TRANSCEND
and PRoFESS, in both of which telmisartan, despite a fall in
blood pressure, did not reduce cardiovascular events better than
placebo. We perhaps also should consider that a majority of
patients in both of these trials were pre-treated with a blocker
of the renin–angiotensin system (RAS). Thus, both trials were eval-
uating the effects of discontinuation of RAS blockade rather than
the effects of starting RAS blockade. Conceivably we are observing,
in both of these studies, a ‘legacy effect’ of pre-randomization RAS
blockade. Also, we should not forget that several ACE inhibitor
trials such as QUIET,10 PEACE,11 PROGRESS,12 and CAMELOT13
did not beat placebo despite a significant fall in blood pressure.
For once, in the present KYOTO study, there was no significant
difference in blood pressure between the two treatment arms. At
study end, 50% more patients were treated with a calcium antag-
onist in the non-ARB arm. Thus, KYOTO is somewhat reminiscent
of VALUE14 in which patients were, in a double-blind prospective
study design, randomized to either valsartan or amlodipine.
However, the results of KYOTO are diametrically different from
those of VALUE in that KYOTO, for a given blood pressure
reduction, showed a 45% reduction of the primary endpoint com-
pared with the non-ARB arm. This benefit was driven mainly by
stroke and, somewhat surprisingly, angina, while there was no sig-
nificant difference in myocardial infarction, heart failure, and all-
cause mortality. In contrast, in VALUE, stroke, if anything, was
reduced less well in the valsartan arm than in the amlodipine
arm. While the disparity in blood pressure control in favour of
amlodipine may have confounded the interpretation of the
results of the (double-blind) VALUE trial, in (open label)
KYOTO, despite the difference in treatment options, surprisingly
exactly the same blood pressure reduction was achieved in the
ARB and non-ARB arm throughout the study. Similar to
VALUE,14 the risk of new-onset diabetes was significantly less in
the valsartan than in the non-ARB arm.
Could the different results of VALUE and KYOTO be explained
by the study populations? Asians may be particularly receptive to
the protective effects of ARBs, as was shown in RENAAL15
where most of the benefits occurred in the Asian subpopulation.
Cerebrovascular disease is more prevalent and coronary artery
disease less prevalent in Asians than in western societies. Not sur-
prisingly, therefore, a reduction of strokes is easier to document
than a reduction of coronary artery disease, as was shown in
both the JIKEI-Heart Study and KYOTO. With regard to angina,
we should remember that this is a rather soft endpoint and that
because of the open label design, investigators were fully aware
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of the treatment being administered. We find it somewhat difficult
to believe that an ARB should be better in preventing angina than a
calcium antagonist, as was observed in both KYOTO and the JIKEI-
Heart Study.
In contrast to JIKEI and KYOTO, in the other two similarly
designed ARB studies in the Asian population, i.e. CASE-J and
HIJ-CREATE, ARB treatment with candesartan did not reduce
morbidity and mortality better than non-ARB therapy. Whether
the difference in outcome between the two valsartan and the
two candesartan studies is due to chance or to differences in the
ARB molecule, in study design, in the patient population, or in
the concomitant medication cannot be determined.
In KYOTO, adverse events were uncommon and medication
was well tolerated. This is not surprising since many studies have
documented that ARBs are exceedingly well tolerated. In fact, in
a few studies in which ARBs were compared with a placebo,
patients on ARB therapy had significantly fewer headaches than
those on placebo. In a thorough Cochrane meta-analysis, withdra-
wal rates due to adverse effects in a total of 46 studies and 13 451
patients were significantly lower on ARBs than on placebo [RR
0.68 (95% CI 0.54–0.87)].16 In contrast, the Cochrane
meta-analysis of 92 studies and 12 954 patients documented that
ACE inhibitors are not better tolerated than placebo [RR
0.85(95% CI 0.67–1.07)].17
The low withdrawal rates in the ARB arm would indicate that
hypertension is perhaps not necessarily such an asymptomatic
disease as we thought and taught. Low-grade headache, fatigue,
and other non-specific symptoms may be associated with sustained
blood pressure elevation. A reduction of blood pressure by an
ARB or an ACE inhibitor may reduce such low-grade symptoms
better than does placebo. However, the inherent adverse effects
of the ACE inhibitor (cough and, uncommonly, angioedema)
seem to abolish the overall achieved benefit. Indeed, head to
head comparisons suggest a better tolerability of ARBs than of
ACE inhibitors.18
The impressive results of the KYOTO study lead to the question
of whether ARBs as a class have come of age and should now be con-
sidered as preferred or baseline therapy in hypertension. The
answer, with regard to safety and efficacy, could be a resounding
yes, i.e. if efficacy were defined as blood pressure reduction.
However, blood pressure is merely a surrogate endpoint which cor-
relates to some extent with the true endpoint, i.e. heart attack,
stroke, and death. As the above meta-analysis demonstrates, ARBs
are efficacious and even superior to other drug classes in stroke
Figure 1 Odds ratio for stroke. There was a significant reduction in the risk of stroke with ARBs compared with controls. The size of the
markers represents the weight of each trial. Meta-analysis was performed using the search terms ‘angiotensin receptor blockers’ with the
inclusion criteria of being a randomized comparison with follow-up for at least 1 year, enrolling non-heart failure patients and evaluating out-
comes of interest.
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prevention but their efficacy with regard to coronary events remains
uncertain. Thus, if efficacy is defined as reduction in overall cardio-
vascular events and mortality, the answer, in view of the data in
aggregate, remains no, or perhaps, not yet.
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Acute episode of an arrhythmogenic right ventricular cardiomyopathy with
vast necroses exclusively in right ventricular myocardium
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We describe the case of an athlete aged 18 years
who died of sudden cardiac arrest without
previously having been diagnosed with heart
disease. The autopsy did not reveal signs of
intoxication or endo-/myocarditis, including nega-
tive results for cardiotropic virus, and coronary
heart disease/vasculitis was excluded by coronary
angiography and histology.
In contrast, cardiac morphology showed
classical signs of arrhythmogenic right ventricular
cardiomyopathy (ARVC) with diffuse replacement
of RV myocardium by fibro-fatty tissue (Panel A),
detection of abnormal long desmosomes (Panel
A, inset) and immunohistochemical lack of
plakoglobin1 (Panel B) but strong expression of
N-cadherin (Panel B, inset). More interestingly
and exclusively in RV myocardium but not in left
ventricle nor both atrias, large areas of acute/
subacute cardiomyocyte necroses were detected
(Panels C and D) with mild inflammatory infiltrates (Panel C), myocytolysis with loss of myofibrils2 (Panel C, inset) and myocardial
contraction bands (Panel D) with hypercontracted sarcomeres (Panel D, inset)
Although death of single myocytes has been reported in ARVC,3 the vast necroses in RV myocardium shown here with an increase
of the MB isoform of creatine kinase (CK-MB 85U/l; CK 530 U/l) detected in a blood sample collected immediately after start of
reanimation have so far not been described and might be the morphological correlate of an acute episode of ARVC. In our
opinion, these data confirm the ‘degenerative hypothesis’4 suggesting that the replacement of the RV myocardium is progressive
with time starting from the epicardium and expanding transmurally to the endocardium3 and underline the relevance of markers
as plakoglobin in preventing such fatal courses of ARVC.
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